Q-omics provides the consensus-scored IGKJ5 profile across patient tissues and cancer cell-line models. IGKJ5 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, IGKJ5 is differentially expressed in 7, with the highest sampling consensus in LUAD. Additionally, IGKJ5 RNA expression shows 14,286 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, LUAD, and LSCC as cancer lineages where IGKJ5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IGKJ5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IGKJ5 survival associations across molecular data types. IGKJ5 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IGKJ5 RNA expression–survival associations across cancer types. High IGKJ5 expression shows unfavorable associations in LGG, but favorable associations in HNSC, SKCM, LUAD, OV and UCEC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for IGKJ5 RNA expression.
This table summarizes IGKJ5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for IGKJ5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IGKJ5 shows lower tumor expression in BRCA and STAD and higher tumor expression in LUAD, HNSC, UCEC and KIRC. The LUAD box plot shows higher IGKJ5 RNA expression in tumor versus normal tissue (log2 FC = +2.838, t-test p < 0.001).
This table shows molecular features associated with IGKJ5 in patient tissues and cancer cell lines. In patient samples, IGKJ5 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
